The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: An observational study

Cardiology Research and Practice

Volumn 1, Issue 1, 2012, Pages

  Dent, Susan ^a   Hopkins, Sean ^b   Graham, Nadine ^b   Johnson, Christopher ^a   Law, Angeline ^a   Campbell, Michelle ^b   Crawley, Freya ^b   Allen, Kathleen ^b   Turek, Michele ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; DEMOGRAPHY; DRUG WITHDRAWAL; EARLY STAGE BREAST CANCER; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MULTIDISCIPLINARY APPROACH; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84874893979     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2012/135819     Document Type: Article

References (14)

1. Jardines L., Goyal S., Fisher P., Breast Cancer Overview: Risk Factors, Screening, Genetic Testing, and Prevention 2011 14th Cancer Management Handbook
2. Early Breast Cancer Trialists' Collaborative Group, Polychemotherapy for early breast cancer: an overview of the randomised trials. The Lancet 1998 352 9132 930 942 2-s2.0-0032547564 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
3. Slamon D. J., Clark G. M., Wong S. G., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 4785 177 182 2-s2.0-0023084858 (Pubitemid 17231334)
4. Feldman A. M., Lorell B. H., Reis S. E., Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000 102 3 272 274 2-s2.0-0034682589 (Pubitemid 30457574)
5. Perez E. A., Romond E. H., Suman V. J., Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology 2011 29 25 3366 3373
6. Gianni L., Dafni U., Gelber R. D., Azambuja E., Muehlbauer S., Goldhirsch A., Untch M., Smith I., Baselga J., Jackisch C., Cameron D., Mano M., Pedrini J. L., Veronesi A., Mendiola C., Pluzanska A., Semiglazov V., Vrdoljak E., Eckart M. J., Shen Z., Skiadopoulos G., Procter M., Pritchard K. I., Piccart-Gebhart M. J., Bell R., Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology 2011 12 3 236 244 2-s2.0-79952041937 10.1016/S1470-2045(11)70033-X
7. Robert N. J., Eiermann W., Pienkowski T., BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up. Journal of Clinical Oncology 2007 23, article 556
8. Romond E. H., Perez E. A., Bryant J., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer (Joint Report Of The NSABP B-31 And NCCTG N9831 Trials). The New England Journal of Medicine 2005 353 1673 1684 (Pubitemid 41464706)
9. Smith I., Procter M., Gelber R. D., 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 2007 369 29 36 10.1016/S0140-6736(07)60028-2 (Pubitemid 46039831)
10. Moja L., Brambilla C., Compagnoni A., Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews 2012 4 CD006243
11. Dent S. F., Vandermeer L. A., Spaans J. N., Adjuvant trastuzumab in early stage breast cancer: is cardiac dysfunction clinically significant. Journal of Clinical Oncology 2007 25 supplement 18S, abstract no. 11072
12. Hajra L., Fralick J., Sue J., Trastuzumab-mediated cardiotoxicity in the non trial setting: Evaluation of patient receiving adjuvant trastuzumab at an academic cancer centre. Proceedings of the ASCO Breast Cancer Symposium 2007. abstract no 241
13. Mackey J. R., Clemons M., Côté M. A., Delgado D., Dent S., Paterson A., Provencher L., Sawyer M. B., Verma S., Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Current Oncology 2008 15 1 24 35 2-s2.0-51649092308 10.3747/co.2008.199
14. Romond E. H., Perez E. A., Bryant J., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine 2005 353 1673 1684 (Pubitemid 41464706)